LON:UPR
Uniphar PLC
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
362.35p
Buy <=wait / entry
321.67p
Trim >=take some off
395.00p
Thesis breakNet debt failing to trend towards the stated target range for two consecutive re...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 26% | 100 / 100 | 26.0 |
| Base case | 49% | 62 / 100 | 30.4 |
| Bear case | 25% | 10 / 100 | 2.5 |
| Weighted conviction | 59 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- H1 2026 adjusted EPS growth of approximately 11% with 7% organic gross profit growth across Pharma, Medtech, and Supply Chain & Retail divisions
- Unchanged full-year expectations for 2026 and long-term target of EUR 200m EBITDA by 2028 with over 80% organic growth
- Deutsche Bank upgrade to 'buy' rating with 8 analysts recommending buy and average price target implying +15.78% upside